Get the Stockscreener App
5.22
4.22%
-0.23
After Hours:
5.23
0.01
+0.19%
Larimar Therapeutics Inc stock is traded at $5.22, with a volume of 2.30M.
It is down -4.22% in the last 24 hours and up +70.03% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$5.45
Open:
$5.36
24h Volume:
2.30M
Relative Volume:
0.62
Market Cap:
$433.73M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-6.2143
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
-5.43%
1M Performance:
+70.03%
6M Performance:
+32.49%
1Y Performance:
+64.15%
1-Day Range:
$5.185
$5.546
1-Week Range:
$4.92
$5.7265
52-Week Range:
$1.61
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
5.22 | 452.84M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March - The Manila Times
Larimar Therapeutics price target raised to $12 from $11 at Wedbush - Yahoo Finance
FDA Grants Breakthrough Status to Larimar’s Nomlabofusp - MyChesCo
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026 - Meyka
LRMR Stock Rating Maintained Outperform by Wedbush, Price Target Raised to $12 | LRMR Stock News - GuruFocus
Wedbush raises Larimar Therapeutics stock price target to $12 By Investing.com - Investing.com Canada
Wedbush raises Larimar Therapeutics stock price target to $12 - Investing.com
Larimar Therapeutics (NASDAQ:LRMR) Price Target Raised to $12.00 - MarketBeat
Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases - Quiver Quantitative
LRMR News & Events - Intellectia AI
Larimar Therapeutics: Deerfield entities buy $25m in stock By Investing.com - Investing.com South Africa
Larimar Therapeutics: Deerfield entities buy $25m in stock - Investing.com Australia
James Flynn Acquires 5,000,000 Shares of Larimar Therapeutics (NASDAQ:LRMR) Stock - MarketBeat
Insider Buying: Frank Thomas Acquires Additional Shares of Larimar Therapeutics Inc (LRMR) - GuruFocus
Wedbush Adjusts Larimar Therapeutics PT to $12 From $11, Maintains Outperform Rating - marketscreener.com
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? - Yahoo Finance
Larimar Therapeutics Announces Upsized Public Equity Offering - TipRanks
Larimar Therapeutics Prices $5.00 Public Offering, Nets ~$107.6 Million as Option Is Exercised - TradingView
LRMR Should I Buy - Intellectia AI
Larimar Therapeutics prices $100M stock offering at $5 per share - Investing.com Australia
Larimar Therapeutics Prices Upsized $100 Million Public Stock Offering - marketscreener.com
Larimar Therapeutics stock falls 8% on upsized $100 million offering By Investing.com - Investing.com Canada
What is Lifesci Capital's Estimate for LRMR FY2025 Earnings? - MarketBeat
Larimar Therapeutics Prices Upsized 20 Mln Public Offering At $5.00 Per Share, Stock Down - Nasdaq
Larimar Therapeutics (LRMR) Upsizes Public Offering to Raise $10 - GuruFocus
Larimar Therapeutics announces pricing of upsized $100 million underwritten public offering - marketscreener.com
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
LRMR Expands Offering to $100 Million - GuruFocus
Larimar Therapeutics Prices Upsized Public Offering - Intellectia AI
Larimar Therapeutics, Inc. Prices Upsized Public Offering of 20 Million Shares at $5.00 Each - Quiver Quantitative
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering - Stock Titan
Larimar Therapeutics launches $75M public stock offering By Investing.com - Investing.com Australia
Larimar Therapeutics Announces Pricing Of Upsized $100 Million Underwritten Public Offering - TradingView
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering - Benzinga
Larimar Therapeutics launches proposed $75 million public offering - MSN
Press Release: Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering - 富途牛牛
Larimar Therapeutics launches $75M public stock offering - Investing.com
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering - Bitget
Rare-disease biotech Larimar seeks $75M to fund key drug - Stock Titan
Citigroup Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $14.00 - MarketBeat
LRMR Analyst Update: Citigroup Raises Price Target for Larimar T - GuruFocus
Laminar Therapeutics Stock Is Popping Today: What's Going On? - Benzinga
Larimar Therapeutics (NASDAQ:LRMR) Hits New 1-Year High After Analyst Upgrade - MarketBeat
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Larimar Therapeutics Sees Unusually High Options Volume (NASDAQ:LRMR) - MarketBeat
Larimar’s Stock Soars After FDA Grants Breakthrough Therapy Designation - StocksToTrade
LRMR: Wedbush Reiterates Outperform Rating at $11 | LRMR Stock N - GuruFocus
Larimar Therapeutics' (LRMR) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Lifesci Capital Upgrades Larimar Therapeutics (NASDAQ:LRMR) to "Strong-Buy" - MarketBeat
Why did Larimar Therapeutics’ stock surge over 30% pre-market today? - MSN
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Larimar Therapeutics Inc Stock (LRMR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hamilton Thomas Edward | Director |
Feb 27 '26 |
Buy |
5.00 |
100,000 |
500,000 |
664,798 |
| THOMAS FRANK E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
7,000 |
| SHERMAN JEFFREY W | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
5,000 |
| Flynn James E | Director |
Jul 31 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
9,538,945 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):